ES2263182T3 - Composicion adecuada para el tratamiento de laminitis equina. - Google Patents

Composicion adecuada para el tratamiento de laminitis equina.

Info

Publication number
ES2263182T3
ES2263182T3 ES97948262T ES97948262T ES2263182T3 ES 2263182 T3 ES2263182 T3 ES 2263182T3 ES 97948262 T ES97948262 T ES 97948262T ES 97948262 T ES97948262 T ES 97948262T ES 2263182 T3 ES2263182 T3 ES 2263182T3
Authority
ES
Spain
Prior art keywords
composition
arg
weight
equine
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97948262T
Other languages
English (en)
Spanish (es)
Inventor
Meri Charmyne Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMK Pharmaceuticals Corp
Original Assignee
Cellegy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellegy Pharmaceuticals Inc filed Critical Cellegy Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2263182T3 publication Critical patent/ES2263182T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES97948262T 1996-11-19 1997-11-17 Composicion adecuada para el tratamiento de laminitis equina. Expired - Lifetime ES2263182T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/752,415 US5891472A (en) 1996-11-19 1996-11-19 Treatment of equine laminitis
US752415 2000-12-29

Publications (1)

Publication Number Publication Date
ES2263182T3 true ES2263182T3 (es) 2006-12-01

Family

ID=25026227

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97948262T Expired - Lifetime ES2263182T3 (es) 1996-11-19 1997-11-17 Composicion adecuada para el tratamiento de laminitis equina.

Country Status (10)

Country Link
US (3) US5891472A (enExample)
EP (1) EP0946147B1 (enExample)
JP (1) JP2001509136A (enExample)
AT (1) ATE326948T1 (enExample)
AU (1) AU5435998A (enExample)
BR (1) BR9714573A (enExample)
CA (1) CA2273183A1 (enExample)
DE (1) DE69735949T2 (enExample)
ES (1) ES2263182T3 (enExample)
WO (1) WO1998022090A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
WO2000024377A1 (en) * 1998-10-23 2000-05-04 Idea Innovative Dermale Applikationen Gmbh Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
AP1682A (en) 2000-08-11 2006-11-27 David R Whitlock Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same.
JP2002136025A (ja) * 2000-10-26 2002-05-10 Mitsubishi Electric Corp 電磁機器
US6780849B2 (en) 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US6833139B1 (en) 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
US20050244382A9 (en) * 2002-01-11 2005-11-03 Whitlock David R Compositions including ammonia oxidizing bacteria and methods of using same
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20040092819A1 (en) * 2002-08-16 2004-05-13 Hmt High Medical Technologies Ag Method for treating laminitis in horses, ponies and other equines with acoustic waves
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US6936273B2 (en) * 2002-12-20 2005-08-30 Idexx Laboratories, Inc. Liposomal analgesic formulation and use
WO2005030147A2 (en) * 2003-09-26 2005-04-07 Whitlock David R Methods of using ammonia oxidizing bacteria
EP1732577B1 (en) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topical delivery of l-arginine to improve body and skin appearance
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
JP2007532697A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
US7731993B2 (en) * 2004-11-17 2010-06-08 Lindsey Berkson Composition for treating a dermal anomaly
WO2006055726A2 (en) * 2004-11-17 2006-05-26 Lindsey Berkson Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US7744928B2 (en) * 2006-04-14 2010-06-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treatment of lesioned sites of body vessels
US8221690B2 (en) 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US7975699B2 (en) 2007-10-30 2011-07-12 The Invention Science Fund I, Llc Condoms configured to facilitate release of nitric oxide
US7862598B2 (en) 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20100292280A1 (en) * 2007-04-15 2010-11-18 Oron Zachar Anti-pyretic vasodilators
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8349262B2 (en) 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
CA2728727C (en) * 2008-06-24 2018-01-23 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
US20100227895A1 (en) * 2009-03-05 2010-09-09 Mpco- The Magic Powder Company Method for treating equine laminitis
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
EP2658551B1 (en) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
JP2014508166A (ja) * 2011-03-17 2014-04-03 トランスダーマル バイオテクノロジ インコーポレーテッド 局所的一酸化窒素システム及びその使用方法
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20160058721A1 (en) 2013-04-01 2016-03-03 Daiichi Sankyo Company, Limited Formulation for treating equine inflammation
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
CN106456678A (zh) 2014-04-15 2017-02-22 Ao生物医学有限责任公司 氨氧化型亚硝化单胞菌菌株d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
US11344508B2 (en) 2016-11-09 2022-05-31 Provita Eurotech Ltd Antimicrobial formulations for the improved treatment of veterinary hoof infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2440371A1 (fr) * 1978-10-31 1980-05-30 Fisons Ltd Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
IE54286B1 (en) * 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
CH681427A5 (enExample) * 1987-07-01 1993-03-31 Zambon Spa
CH680223A5 (enExample) * 1989-07-17 1992-07-15 Pier Luigi Prof Dr Luisi
DE4305881C1 (de) * 1993-02-26 1994-03-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
DE69426986T2 (de) * 1993-08-28 2001-10-25 The University Of Sheffield, Sheffield Behandlung von laminitis
GB2292520B (en) * 1994-08-25 1998-09-02 Univ Sheffield Transdermal dressings for animals
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis

Also Published As

Publication number Publication date
AU5435998A (en) 1998-06-10
WO1998022090A1 (en) 1998-05-28
US6045827A (en) 2000-04-04
CA2273183A1 (en) 1998-05-28
EP0946147B1 (en) 2006-05-24
DE69735949D1 (de) 2006-06-29
ATE326948T1 (de) 2006-06-15
EP0946147A1 (en) 1999-10-06
DE69735949T2 (de) 2007-01-04
BR9714573A (pt) 2002-07-23
US5891472A (en) 1999-04-06
US6287601B1 (en) 2001-09-11
EP0946147A4 (en) 2001-12-12
JP2001509136A (ja) 2001-07-10

Similar Documents

Publication Publication Date Title
US6045827A (en) Treatment of equine laminitis
ES2391914T3 (es) Formulación farmacéutica tópica
EP0672422B1 (en) Antiinflammatory and analgesic transdermal gel containing Ketoprofen
ES2429443T3 (es) Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada
ES3011984T3 (en) Treatment of erectile dysfunction
ES2330295B1 (es) Formulacion topica de ibuprofeno.
JP4387639B2 (ja) 経皮吸収製剤
JP5732471B2 (ja) 溶媒混合物およびビタミンｄ誘導体から成る医薬品組成物または類似体
JPH05178764A (ja) 局所用あるいは経皮用製品におけるジブチルアジペートとイソプロピルミリステートの用途
US4777047A (en) Transdermal application form of calcium antagonists
CN109715138A (zh) 前列环素类似物制剂
ES2659940T3 (es) Composición veterinaria inyectable para animales pequeños
PT2197492E (pt) Novas composições à base de taxóides
ES2234123T3 (es) Preparacion percutanea que contiene clorhidrato de azelastina que tiene buena capacidad de absorcion percutanea e irritacion reducida de la piel.
US11925621B2 (en) Medicinal preparation for external use
ES2220787T3 (es) Composiciones antifungicas a base de cetoconazol, destinadas a un uso topico.
EP0853476B1 (en) Pharmaceutical preparation containing nimesulide for topical use
MXPA99005262A (en) Treatment of equine laminitis
RU2530644C2 (ru) Противоугревая фармацевтическая композиция и способ ее получения
ES2441917B1 (es) Composición farmacéutica para uso en inflamación y dolor
ES2289897B1 (es) Composicion para administracion transdermica de agentes fisiologicamente activos.
KR100212969B1 (ko) 진통소염 외용 액제
BR112014013926B1 (pt) composição farmacêutica aperfeiçoada para melhorar entrega transdérmica de inibidor de pde-5
WO2021232123A1 (pt) Plataforma para mascaramento de sabor
WO2013111817A1 (ja) タクロリムスを含有する水中油型クリーム状組成物